Biogen scraps late-stage study for Parkinson’s drug
BioPharma Dive,
Biogen has disclosed plans to stop a late-stage clinical trial testing one of its drugs as a potential treatment for Parkinson’s…
Biogen has disclosed plans to stop a late-stage clinical trial testing one of its drugs as a potential treatment for Parkinson’s…
Share on PinterestA recent study investigates whether llama nanobodies might help design future Parkinson’s treatments.
. Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity.
. Models of LRRK2-Associated Parkinson's Disease. Adv Neurobiol. 2017;14:163-191.